The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2021Hidden Sorrows of Covid-19: Impact of Stress on Parkinson’s Disease Progression
Study Rationale: People living with Parkinson’s disease (PD) are very sensitive to stress, which worsens motor symptoms (such as tremor) and leads to anxiety and depression. Studies in animals suggest...
-
Research Grant, 2020Targeting of the Raphe-Cortical Pathway to Reduce Levodopa-Induced Psychosis
Study Rationale:
Parkinson’s disease is best known as a movement disorder, yet non-motor symptoms such as anxiety, depression and psychosis afflict over 50 percent of patients and severely impact... -
Research Grant, 2023Leveraging Gene Expression Data to Redefine Parkinson’s Disease and the Pathways Driving Disease in Different Individuals
Study Rationale: People with Parkinson’s disease (PD) share some common problems, such as stiffness, slowness of movement and tremors. However, these symptoms vary in severity, and individuals often...
-
Target Advancement Program, 2021Use of Therapeutic Nanoparticles to Inhibit Toxic Aggregation of Alpha-Synuclein
Study Rationale:
A hallmark of Parkinson’s disease (PD) is the abnormal accumulation of clumps of alpha-synuclein in nerve cells. These improperly folded protein clumps contribute to the symptoms of... -
Therapeutic Pipeline Program, 2016Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease
Study Rationale:
Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life... -
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.